TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed and dated written informed consent obtained before any study-related activities~2. Male subjects with a diagnosis of type 2 diabetes mellitus according to ADA criteria at least 4 months prior to screening~3. Medical history without major pathology (with the exception of type 2 diabetes)~4. On a stable regimen of metformin monotherapy for at least 3 months~5. Aged between 45 and 70 years of age, both inclusive~6. Body mass index (BMI) between 25 and 35kg/m2, both inclusive~Exclusion Criteria:~1. Subjects with type 1 diabetes, MODY or secondary forms of diabetes such as due to pancreatitis~2. History of pancreatitis~3. Current or previous treatment with insulin therapy~4. Treatment with any hypoglycemic medication other than metformin within the three months prior to screening~5. Mean QTc\> 450 msec

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: ACTIVE_COMPARATOR): Placebo dextromethorphan + sitagliptin 100 mg
- Dextromethorphan 30 mg + sitagliptin (Type: EXPERIMENTAL): Dextromethorphan 30 mg + sitagliptin 100 mg
- Dextromethorphan 60 mg + sitagliptin (Type: EXPERIMENTAL): Dextromethorphan 60 mg + sitagliptin 100 mg
- Dextromethorphan 90 mg + sitagliptin (Type: EXPERIMENTAL): Dextromethorphan 90 mg + sitagliptin 100 mg
- Dextromethorphan 30 mg + placebo (Type: EXPERIMENTAL): Dextromethorphan 30 mg + placebo (sitagliptin)
- Dextromethorphan 60 mg + placebo (Type: EXPERIMENTAL): Dextromethorphan 60 mg + placebo (sitagliptin)
- Dextromethorphan 90 mg + placebo (Type: EXPERIMENTAL): Dextromethorphan 90 mg + placebo (sitagliptin)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (dextromethorphan)+ placebo (sitagliptin)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Control Trial of Booster Seat Education Material to Increase Perceived Benefit Among Parents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parents of children 4 thorough 8 years old~* Residing in any Canadian Province~* Fluent in English~* Drive with their child at least once a month~Exclusion Criteria:~- Child has a physical condition that requires special transportation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Current material (Type: ACTIVE_COMPARATOR): Participants in this arm will be shown the online Transport Canada Material that is currently available at: https://www.tc.gc.ca/en/services/road/child-car-seat-safety/installing-using-child-car-seat-booster-seat-seat-belt/stage-3-booster-seats.html
- Enhanced material (Type: EXPERIMENTAL): Participants in this arm will be shown an enhanced version of the online Transport Canada Material, which includes an introduction explaining how booster seats prevent injuries caused by seat belts.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety of Viagra in Men With ED and LUTS Due to Benign Prostatic Hyperplasia (BPH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* clinical diagnosis of erectile dysfunction (ED)~* lower urinary tract symptoms (LUTS)~Exclusion Criteria:~* previous prostate surgery or invasive intervention for BPH~* active urinary tract disease

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Randomized into Study 20110118 (FOURIER; NCT01764633)~Exclusion Criteria:~* Current or known past diagnosis of dementia or mild cognitive impairment (MCI)

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference. Participants continued with their background statin therapy during the course of the study.
- Evolocumab (Type: EXPERIMENTAL): Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference. Participants continued with their background statin therapy during the course of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound-Guided Intercostal Nerve Block for Postoperative Pain Relief in Percutaneous Nephrolitotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients admitted for the removal of renal stones by percutaneous~* nephrolithotomy (PCNL)~* ASA I-II status~Exclusion Criteria:~* Respiratory or cardiac disfunction~* Neuropathy~* Coagulopathy~* BMI (Body mass index)over 30

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: NO_INTERVENTION): Control group: Group that without intercostal nerve block
- nerve block (Type: EXPERIMENTAL): Group that performing intercostal block

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Daily Chlorhexidine Care at the Exit Site in Peritoneal Dialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients \> 20 years old who received PD for more than 3 months~Exclusion Criteria:~* a history of psychological illness or condition that interferes with caring of a wound~* recent (within 1 month) exit-site infection, peritonitis, or tunnel infection~* recent treatment with an antibiotic administered by any route in the last month~* or known hypersensitivity to or intolerance of chlorhexidine or mupirocin

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chlorhexidine gluconate (Type: EXPERIMENTAL): PD (peritoneal dialysis) paitents with daily chlorhexidine exit site care
- Control group (Type: NO_INTERVENTION): PD (peritoneal dialysis) patients with usual (Normal saline) exit site care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Adefovir Dipivoxil for Korean Patients With Chronic Hepatitis B(CHB) Who Have Completed ADF 103814

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Subject has completed ADF103814 and continues with adefovir dipivoxil treatment via prescription without interruption prior enrolment in this extension study.~Availability and willingness of subject to provide written informed consent.~Exclusion Criteria:~Use of immunosuppressive therapy requiring use of more than 5mg of prednisolone(or equivalent) per day, immunomodulatory therapy (including interferon or thymosin) or systemic cytotoxic agents during the study.~Previous or current lamivudine or antiviral therapy Clinical signs of decompensated liver disease as indicated by the protocol Inadequate haematological function defined by the protocol - Documented evidence of active liver disease due to other causes Hepatocellular carcinoma as evidenced by the protocol Any serious or active medical or psychiatric illnesses other than hepatitis B which, in the opinion of the investigator, would interfere with patient treatment, assessment or compliance with the protocol. This would include any uncontrolled clinically significant renal, cardiac, pulmonary, vascular, neurogenic, digestive, metabolic (diabetes, thyroid disorders, adrenal disease), immunodeficiency disorders or cancer.~Active alcohol or drug abuse or history of alcohol or drug abuse considered by the investigator to be sufficient to hinder compliance with treatment, participation in the study or interpretation of results.~Planned for liver transplantation Therapy with nephrotoxic drugs or competitors of renal excretion can be expected during the course of the study.~History of hypersensitivity to nucleoside and/or nucleotide analogues. Inability to comply with study requirements as determined by the study investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antiplatelet vs R-tPA for Acute Mild Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient age ≥18 years;~2. Study treatment can be started within 4.5h;~3. Ischemic stroke confirmed by head CT or MRI;~4. NIHSS score ≤ 5, and ≤ 1 NIHSS score in single item scores such as vision, language, neglect and single limb and no score in consciousness item;~5. Premorbid mRS ≤ 1;~6. Signed informed consent~Exclusion Criteria:~1. Serious neurological deficits before onset ( mRS ≥ 2)；~2. Obvious head injuries or strokes within 3 months；~3. Subarachnoid hemorrhage;~4. History of intracranial hemorrhage;~5. Intracranial tumor, arteriovenous malformation or aneurysm;~6. Intracranial or spinal cord surgery within 3 months;~7. Arterial puncture at a noncompressible site within the previous seven days;~8. Gastrointestinal or urinary tract hemorrhage within the previous 21 days;~9. Major surgery within 1 month;~10. Systolic pressure ≥180 mmHg or diastolic pressure ≥110 mmHg;~11. Blood glucose \< 50 mg/dl (2.7mmol/L);~12. Heparin therapy or oral anticoagulation therapy within 48 hours;~13. Platelet count of \<100,000/mm3 (This does not need to be verified prior to randomization if clinical abnormality is not suspected);~14. Oral warfarin is being taken and INR\>1.6;~15. Abnormal APTT;~16. Pregnancy;~17. Neurological deficit after epileptic seizures;~18. Myocardial infarction within 3 months;~19. Cerebral infarction with definite anticoagulation indications, such as cerebral infarction caused by cardiogenic embolism;~20. Oral administration is not allowed due to dysphagia;~21. allergy to study drugs;~22. Other serious illness that would confound the clinical outcome at 90 days;~23. Participating in other clinical trials within 3 months;~24. patients not suitable for this clinical studies considered by researcher;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspirin+ clopidogrel (Type: EXPERIMENTAL): aspirin 100mg qd and clopidogrel 75mg（300mg in the first day）qd with a total of 10-14 days, then oral aspirin 100mg or clopidogrel 75mg qd lasting for 90 days.
- Alteplase (Type: ACTIVE_COMPARATOR): intravenous alteplase (0.9 mg/kg and maximal dose of 90 mg) was given, and followed by antithrombotic protocol 24 hours after thrombolysis based on clinical guideline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is over 18 years of age.~* Presence of a renal mass.~* Scheduled for surgical resection of renal mass (partial or total nephrectomy, open or laparoscopic technique).~* Expected survival of at least 3 months.~* Eastern Cooperative Oncology Group (ECOG) performance status \< 2.~* The following laboratory results should be within the following limits within the last 2 weeks prior to study day 1:~  * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L~ * Platelet count ≥ 100 x 109/L~ * Serum bilirubin ≤ 2.0 mg/dL~ * Aspartate aminotransaminase (AST) ≤ 2.5 x ULN~ * Alanine aminotransferase (ALT) ≤ 2.5 x ULN~ * Serum creatinine ≤ 2.0 mg/dL (calculated creatinine clearance \>45 ml/min)~* Negative serum pregnancy test; to be performed on female patients of childbearing potential within 24 hours prior to receiving investigational product. All females of childbearing potential must indicate intent to avoid pregnancy and must use an accepted, effective method of contraception for the duration of the study.~* Recovered from toxicity of any prior therapy.~* Able and willing to give valid written informed consent.~Exclusion Criteria:~* Metastasis of primary tumor other than Renal Cell Carcinoma (RCC).~* Prior history of malignancy within the last 5 years.~* Prior exposure to murine proteins or chimeric antibodies.~* Intercurrent medical condition that may limit the amount of antibody to be administered.~* Intercurrent medical condition that renders the patient ineligible for surgery.~* New York Heart Association Class III/IV cardiac disease.~* History of autoimmune hepatitis.~* Chemotherapy, radiotherapy, or immunotherapy within 4 weeks prior to 124I-cG250 infusion on day 1.~* Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study.~* Lack of availability for immunological and clinical follow-up assessments.~* Participation in any other clinical trial involving another investigational product within 4 weeks prior to enrolment.~* Women who are pregnant or breastfeeding.~* Allergy to iodine, hyperthyroidism, or Grave's Disease.~* Known allergic reaction to human serum albumin.~* Contraindication for contrast-enhanced CT or PET/CT.~* Contraindication to potassium iodide intake (see package insert).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 124-Iodine-cG250 (124I-cG250) (Type: OTHER): Single arm study, comparing 124I cG250 PET/CT and CT. Each patient underwent a PET/CT and CT scan days (+/-2days) after receipt of 124I cG250.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults, 18 to 80 years of age~* Meets diagnostic criteria for isolated CD (idiopathic; dystonic symptoms localized to the head, neck, shoulder areas) with at least moderate severity at Baseline (Day 1), defined as a TWSTRS-total score of at least 20, with at least 15 on the TWSTRS-Severity subscale, at least 3 on the TWSTRS-Disability subscale, and at least 1 on the TWSTRS-Pain subscale~Exclusion Criteria:~* Cervical dystonia attributable to an underlying etiology, (e.g., traumatic torticollis or tardive torticollis)~* Predominant retrocollis or anterocollis CD~* Significant dystonia in other body areas, or is currently being treated with BoNT for dystonia in areas other than those associated with isolated CD~* Severe dysphagia (Grade 3 or 4 on the Dysphagia Severity Scale) at Screening or Baseline (prior to study treatment)~* Any neuromuscular neurological conditions that may place the subject at increased risk of morbidity with exposure to BoNT, including peripheral motor neuropathic diseases (e.g., amyotrophic lateral sclerosis and motor neuropathy, and neuromuscular junctional disorders such as Lambert-Eaton syndrome and myasthenia gravis)~* Previous treatment with any BoNT product for any condition within the 14 weeks prior to Screening~* Botulinum Neurotoxin Type A (BoNTA), except the investigational daxibotulinumtoxinA, treatment-experienced subjects who had suboptimal or no treatment response to the most recent BoNTA injection for CD, as determined by the investigator, or history of primary or secondary non-response to BoNTA injections, known to have neutralizing antibodies to BoNTA; or have a history of botulinum toxin type B (rimabotulinumtoxinB \[Myobloc/Neurobloc\]) injection for CD due to non-response or suboptimal response to BoNTA

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DAXI for injection low dose (Type: EXPERIMENTAL): Low Dose Group
- DAXI for injection high dose (Type: EXPERIMENTAL): High Dose Group
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brief Online Help-seeking Barrier Reduction Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants identified as experiencing a mental health crisis by a hybrid human-machine computation system evaluating semantic content of posts made on digital platforms.~Exclusion Criteria:~* Participants who were not identified as experiencing a mental health crisis.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): None
- Intervention (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Evaluation of Propolis Mouthwash With 0.2% Chlorhexidine Mouthwash in Improving the Periodontitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females of age 40-50 years.~* Patients who are willing to receive treatment and give informed consent.~* Patients with probing pocket depth (PPD) of 4mm - 5mm and clinical attachment loss (CAL) of 1-4 mm.~* Presence of bleeding on probing (BOP).~* Patients should not have been subject to periodontal therapy and antibiotic medication in the past 6 months.~* Patients with a minimum of 20 teeth in the oral cavity.~Exclusion Criteria:~* Patients who are allergic to honey products.~* Patients on HRT (hormone replacement therapy) or patients who have not had a menstrual cycle for the last 12 months.~* Patients who had lost teeth because of periodontal disease.~* Patients who are or have been smokers in the past.~* Patients are on any kind of antibiotic therapy at the time of screening.~* Systemic conditions predispose patients to chronic periodontal diseases such as diabetes.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- propolis (Type: EXPERIMENTAL): 5 ml of 20% propolis mouthwash twice a day.
- chlorhexidine (Type: ACTIVE_COMPARATOR): 5 ml of 0.2% chlorhexidine mouthwash twice a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete